BBIO BridgeBio Pharma Inc

Price (delayed)

$60.6

Market cap

$9.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.2

Enterprise value

$9.96B

Highlights
BridgeBio Pharma's gross margin has increased by 7% YoY
BridgeBio Pharma's revenue has plunged by 79% YoY but it has increased by 6% from the previous quarter
The gross profit has plunged by 77% YoY but it has grown by 6% from the previous quarter
BBIO's debt has surged by 193% year-on-year and by 179% since the previous quarter
BBIO's net income has dropped by 79% year-on-year and by 16% since the previous quarter

Key stats

What are the main financial stats of BBIO
Market
Shares outstanding
149.28M
Market cap
$9.05B
Enterprise value
$9.96B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
964.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,143.15
Earnings
Revenue
$8.71M
EBIT
-$477.57M
EBITDA
-$473.12M
Free cash flow
-$471.41M
Per share
EPS
-$4.2
Free cash flow per share
-$3.4
Book value per share
-$2.65
Revenue per share
$0.06
TBVPS
$7.89
Balance sheet
Total assets
$1.09B
Total liabilities
$1.48B
Debt
$1.38B
Equity
-$395.29M
Working capital
$850.39M
Liquidity
Debt to equity
-3.5
Current ratio
9.98
Quick ratio
9.71
Net debt/EBITDA
-1.93
Margins
EBITDA margin
-5,431.3%
Gross margin
100%
Net margin
-5,968.9%
Operating margin
-6,193.3%
Efficiency
Return on assets
-59.6%
Return on equity
-2,257.5%
Return on invested capital
-45.1%
Return on capital employed
-47.8%
Return on sales
-5,482.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
-1.7%
1 week
2.4%
1 month
2.11%
1 year
97.52%
YTD
-14.78%
QTD
-0.59%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$8.71M
Gross profit
$8.71M
Operating income
-$539.5M
Net income
-$519.95M
Gross margin
100%
Net margin
-5,968.9%
BridgeBio Pharma's revenue has plunged by 79% YoY but it has increased by 6% from the previous quarter
BBIO's net income has dropped by 79% year-on-year and by 16% since the previous quarter
The gross profit has plunged by 77% YoY but it has grown by 6% from the previous quarter
BBIO's operating income has dropped by 77% year-on-year and by 14% since the previous quarter

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
964.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,143.15
BBIO's EPS has dropped by 60% year-on-year and by 11% since the previous quarter
BridgeBio Pharma's revenue has plunged by 79% YoY but it has increased by 6% from the previous quarter
The stock's price to sales (P/S) is 68% more than its last 4 quarters average of 573.4

Efficiency

How efficient is BridgeBio Pharma business performance
The ROIC has grown by 49% YoY and by 19% from the previous quarter
The ROA has contracted by 32% YoY and by 12% from the previous quarter
BBIO's ROS is down by 10% since the previous quarter

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 26% smaller than its total liabilities
BBIO's total liabilities has soared by 175% YoY and by 149% QoQ
BBIO's total assets has soared by 55% since the previous quarter and by 10% year-on-year
BBIO's debt has surged by 193% year-on-year and by 179% since the previous quarter
BBIO's debt to equity has dropped by 141% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.